Event: BTOG 2017

0:02:38

The NLCA annual report 2017: findings for lung cancer care in the UK

0:02:41

Asbestos claims - BTOG Raffle Draw with Niamh Sherwood

0:03:45

The evolution of BTOG and thoracic oncology care in the UK

0:31:25

ASCO 2019 - John Conibear

0:01:29

Updates in lung cancer management from the BTOG 2022 Summer Meeting

0:01:28

Early clinical trials of immunotherapy treatment combinations

0:00:53

Expanding the clinical trial portfolio for lung cancer

0:00:45

How to discuss immunotherapy as a treatment option with lung cancer patients

0:01:28

How to integrate supportive care in oncology?

0:01:02

The ICLIO Visiting Experts Program

0:01:54

Balancing the benefits and costs of immunotherapy in the treatment of lung cancer

0:01:41

Whole mutational burden as a predictive marker for response to immunotherapy

0:03:34

Repeat biopsy in lung cancer patients with EGFR mutation

0:01:45

Patient support NETworks: the NET Patient Foundation

0:20:25

Lung Cancer: Current Therapies and New Targeted Treatments

0:00:54

Current practices for x-ray reporting in the UK

0:05:02

Going beyond PD-L1 testing for lung cancer immunotherapy

0:01:10

How the AURA3 trial has changed conversations about re-biopsy in second-line lung cancer treatment

0:01:18

Vinorelbine in Mesothelioma: the upcoming VIM trial

0:01:44

PD-L1 testing in first-line treatment of NSCLC

0:02:10

Novel targets and biomarkers in mesothelioma

0:01:34

The evolution of cancer supportive care

0:01:33

Exciting randomized trials for mesothelioma: checkpoint inhibitor monotherapies and vinorelbine

0:01:18

Intro Africa France Forum 2017 .Rencontres B2B.Presentation Travaux. Mr Charles Auguste banny